Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 3 2Phase NA 1Phase 1 1

Status

Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Carcinoma, Ovarian Epithelial 3Ovarian Neoplasms 2

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × oregovomab × Gynecologic × Clear all
NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.

Phase 1/2 Active not recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT03100006 2022-06-13

ORION-01

National Cancer Centre, Singapore

Phase 1/2 Terminated
13 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT04620954 2021-12-01

ORION-02

National Cancer Centre, Singapore

Phase 1/2 Unknown
31 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Unither Pharmaceuticals

Phase 1/2 Terminated
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡